Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of ($0.78), $0.11 better than the analyst estimate of ($0.89). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE